BOSTON, May 17, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest update for their competitive landscape map for the Chronic Kidney Disease (CKD) market. This particular landscape highlights over 90 international companies with drugs and devices currently on the market and in development addressing CKD and its sequelae.
TechAtlas' analysts have evaluated each technology according to the parameters that dictate their commercial competitiveness, including benefit/risk, cost, convenience, and reimbursement dynamics (e.g., exposure to bundling). For example, non-calcium-based phosphate binders will compete on price as oral drugs enter the dialysis bundle, but certain iron-based agents will have an advantage since they also reduce the need for expensive anemia drugs. Among future anemia agents, injectable antibodies and RNAi targeting hepcidin will have different times to onset of action, and both will compete against the more convenient oral HIF-PH inhibitors. However, all of these anemia therapies will face pricing pressure in a bundled dialysis environment and will be better received for treating anemia in pre-dialysis patients but only in certain geographies.
The TechAtlas map graphically presents every CKD-related technology, old and new, in its proper context to clearly show the relati
|SOURCE TechAtlas Group|
Copyright©2012 PR Newswire.
All rights reserved